A BMI of 27 with type 2 diabetes is one of the clearest qualification pathways that exists
Quick Comparison Clinical Trial Results: What the Data Actually Shows Retatrutide TRIUMPH Phase 3 Program Retatrutide has completed two Phase 3 trials in obesity populations, both showing nearly identical results despite different patient populations and durations which is exactly what a robust efficacy signal looks like
Eat slowly and chew thoroughly
Results from double-blind, placebo-controlled trials have recently been published [99,100,101]
Typically, you may be a candidate for GLP-1 therapy if you meet one of the following criteria: A BMI of 30 or higher, which is classified as obesity
However, Wegovy uses semaglutide, which has been studied for many years